ClassID:

96533

C07J31/003 - CPC Classification

Classification description:

Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton

Recent Application in this class:
#1
20250313592
2025-10-09

PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES

#2
20250257092
2025-08-14

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

#3
20230192756
2023-06-22

Neuroactive steroids, compositions, and uses thereof

#4
20210238219
2021-08-05

NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS

#5
20210155653
2021-05-27

METHOD FOR HOMOGENIZING BILE ACID DERIVATIVES

#6
20210147470
2021-05-20

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

#7
20210130286
2021-05-06

CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION

#8
20200157140
2020-05-21

NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS

#9
20190135856
2019-05-09

NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS

#10
20180369257
2018-12-27

Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient

#11
20180362573
2018-12-20

Neuroactive steroids, compositions, and uses thereof

#12
20180127457
2018-05-10

NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS

#13
20170051008
2017-02-23

Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

#14
20150072962
2015-03-12

NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS

#15
20140256932
2014-09-11

Process for preparing 17-substituted steroids

#16
20140094619
2014-04-03

Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties

#17
20130102577
2013-04-25

Ship inhibitors and uses thereof

#18
20110092473
2011-04-21

Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties

#19
20110009372
2011-01-13

Compounds and compositions

#20
20070275936
2007-11-29

Formulations and Treatment Methods

#21
20070129282
2007-06-07

Pharmaceutical treatments and compositions